These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 36440599)

  • 1. Efficacy of epi-1 modified epirubicin and curcumin encapsulated liposomes targeting-EpCAM in the inhibition of epithelial ovarian cancer cells.
    Wang YJ; Tang L; Lu XH; Liu JT; Wang YY; Geng HX; Li XT; An Q
    J Liposome Res; 2023 Jun; 33(2):197-213. PubMed ID: 36440599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted delivery of epirubicin to tumor-associated macrophages by sialic acid-cholesterol conjugate modified liposomes with improved antitumor activity.
    Zhou S; Zhang T; Peng B; Luo X; Liu X; Hu L; Liu Y; Di D; Song Y; Deng Y
    Int J Pharm; 2017 May; 523(1):203-216. PubMed ID: 28336455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of R
    Liu JJ; Tang W; Fu M; Gong XQ; Kong L; Yao XM; Jing M; Cai FY; Li XT; Ju RJ
    Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):1947-1960. PubMed ID: 31079495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RPV-modified epirubicin and dioscin co-delivery liposomes suppress non-small cell lung cancer growth by limiting nutrition supply.
    Kong L; Cai FY; Yao XM; Jing M; Fu M; Liu JJ; He SY; Zhang L; Liu XZ; Ju RJ; Li XT
    Cancer Sci; 2020 Feb; 111(2):621-636. PubMed ID: 31777993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liposomes, modified with PTD(HIV-1) peptide, containing epirubicin and celecoxib, to target vasculogenic mimicry channels in invasive breast cancer.
    Ju RJ; Li XT; Shi JF; Li XY; Sun MG; Zeng F; Zhou J; Liu L; Zhang CX; Zhao WY; Lu WL
    Biomaterials; 2014 Aug; 35(26):7610-21. PubMed ID: 24912818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of multifunctional targeting epirubicin liposomes in the treatment of non-small-cell lung cancer.
    Song XL; Ju RJ; Xiao Y; Wang X; Liu S; Fu M; Liu JJ; Gu LY; Li XT; Cheng L
    Int J Nanomedicine; 2017; 12():7433-7451. PubMed ID: 29066893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epirubicin loaded with propylene glycol liposomes significantly overcomes multidrug resistance in breast cancer.
    Zhao YZ; Dai DD; Lu CT; Chen LJ; Lin M; Shen XT; Li XK; Zhang M; Jiang X; Jin RR; Li X; Lv HF; Cai L; Huang PT
    Cancer Lett; 2013 Mar; 330(1):74-83. PubMed ID: 23186833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epirubicin-encapsulated long-circulating thermosensitive liposome improves pharmacokinetics and antitumor therapeutic efficacy in animals.
    Wu Y; Yang Y; Zhang FC; Wu C; Lü WL; Mei XG
    J Liposome Res; 2011 Sep; 21(3):221-8. PubMed ID: 20929434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An Application of Tumor-Associated Macrophages as Immunotherapy Targets: Sialic Acid-Modified EPI-Loaded Liposomes Inhibit Breast Cancer Metastasis.
    Meng X; Wang M; Zhang K; Sui D; Chen M; Xu Z; Guo T; Liu X; Deng Y; Song Y
    AAPS PharmSciTech; 2022 Oct; 23(8):285. PubMed ID: 36258152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancement of in vitro antitumour activity of epirubicin in HER2+ breast cancer cells using immunoliposome formulation.
    Khaleseh F; Hemmati Azandaryani A; Fathian Kolahkaj F; Khazaei M; Derakhshandeh K
    IET Nanobiotechnol; 2021 May; 15(3):257-265. PubMed ID: 34694666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced antitumor efficacy using epirubicin and schisandrin B co-delivery liposomes modified with PFV via inhibiting tumor metastasis.
    Jing M; Bi XJ; Yao XM; Cai F; Liu JJ; Fu M; Kong L; Liu XZ; Zhang L; He SY; Jia LQ; Li XT
    Drug Dev Ind Pharm; 2020 Apr; 46(4):621-634. PubMed ID: 32162988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polysialic acid-modifying liposomes for efficient delivery of epirubicin, in-vitro characterization and in-vivo evaluation.
    Zhang T; Zhou S; Hu L; Peng B; Liu Y; Luo X; Song Y; Liu X; Deng Y
    Int J Pharm; 2016 Dec; 515(1-2):449-459. PubMed ID: 27789365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sialic acid conjugate-modified liposomes enable tumor homing of epirubicin via neutrophil/monocyte infiltration for tumor therapy.
    Ding J; Sui D; Liu M; Su Y; Wang Y; Liu M; Luo X; Liu X; Deng Y; Song Y
    Acta Biomater; 2021 Oct; 134():702-715. PubMed ID: 34339869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polysialic acid-polyethylene glycol conjugate-modified liposomes as a targeted drug delivery system for epirubicin to enhance anticancer efficiency.
    Zhang T; Zhou S; Hu L; Peng B; Liu Y; Luo X; Liu X; Song Y; Deng Y
    Drug Deliv Transl Res; 2018 Jun; 8(3):602-616. PubMed ID: 29536348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vitamin C-driven epirubicin loading into liposomes.
    Lipka D; Gubernator J; Filipczak N; Barnert S; Süss R; Legut M; Kozubek A
    Int J Nanomedicine; 2013; 8():3573-85. PubMed ID: 24101870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overcoming multidrug resistance using liposomal epirubicin and antisense oligonucleotides targeting pump and nonpump resistances in vitro and in vivo.
    Lo YL; Liu Y; Tsai JC
    Biomed Pharmacother; 2013 May; 67(4):261-7. PubMed ID: 23540284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accelerated drug release and clearance of PEGylated epirubicin liposomes following repeated injections: a new challenge for sequential low-dose chemotherapy.
    Yang Q; Ma Y; Zhao Y; She Z; Wang L; Li J; Wang C; Deng Y
    Int J Nanomedicine; 2013; 8():1257-68. PubMed ID: 23576868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-delivery of epirubicin and paclitaxel using an estrone-targeted PEGylated liposomal nanoparticle for breast cancer.
    Tang H; Chen J; Wang L; Li Q; Yang Y; Lv Z; Bao H; Li Y; Luan X; Li Y; Ren Z; Zhou X; Cong D; Liu Z; Jia J; Chen H; Zhao W; Meng Q; Sun F; Pei J
    Int J Pharm; 2020 Jan; 573():118806. PubMed ID: 31678519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting Epirubicin Plus Quinacrine Liposomes Modified with DSPE-PEG2000-C(RGDfK) Conjugate for Eliminating Invasive Breast Cancer.
    Sun MG; Shi JF; Li XY; Zhao Y; Ju RJ; Mu LM; Yan Y; Li XT; Zeng F; Lu WL
    J Biomed Nanotechnol; 2015 Aug; 11(8):1339-53. PubMed ID: 26295137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipid nanoparticle-based co-delivery of epirubicin and BCL-2 siRNA for enhanced intracellular drug release and reversing multidrug resistance.
    Yu M; Han S; Kou Z; Dai J; Liu J; Wei C; Li Y; Jiang L; Sun Y
    Artif Cells Nanomed Biotechnol; 2018 Mar; 46(2):323-332. PubMed ID: 28393563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.